Aura Biosciences, Inc. (NASDAQ:AURA) Sees Significant Decline in Short Interest

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,120,000 shares, a decrease of 13.2% from the February 13th total of 1,290,000 shares. Based on an average trading volume of 158,600 shares, the days-to-cover ratio is currently 7.1 days. Approximately 2.5% of the company’s shares are sold short.

Aura Biosciences Stock Down 1.6 %

Shares of NASDAQ AURA opened at $7.42 on Wednesday. The firm has a market cap of $370.64 million, a PE ratio of -4.29 and a beta of 0.30. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The company’s fifty day simple moving average is $7.68 and its 200 day simple moving average is $8.67.

Analysts Set New Price Targets

Separately, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 23,045 shares of company stock worth $177,242. 5.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AURA. BNP Paribas Financial Markets acquired a new position in Aura Biosciences during the fourth quarter worth $50,000. China Universal Asset Management Co. Ltd. acquired a new position in Aura Biosciences during the fourth quarter worth $87,000. ProShare Advisors LLC acquired a new position in Aura Biosciences during the fourth quarter worth $127,000. Harvest Investment Services LLC acquired a new position in Aura Biosciences during the fourth quarter worth $133,000. Finally, AlphaQuest LLC acquired a new position in Aura Biosciences during the fourth quarter worth $136,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.